Previous close | 1.4500 |
Open | 1.4500 |
Bid | 0.1500 |
Ask | 2.9000 |
Strike | 30.00 |
Expiry date | 2024-01-19 |
Day's range | 1.4000 - 1.4500 |
Contract range | N/A |
Volume | |
Open interest | 528 |
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.